They found that in patients with BRAF-mutated melanoma brain metastases, first-line treatment with BRAF/MEK inhibitor therapy improved overall survival compared to patients treated with first-line therapy with anti-PD1 (P = 0.043) (71). Here, PDCD1 is linked to melanoma.